Environmental or self-antigens and homotypic interactions induce BCR and Toll-like receptor (TLR) signaling, amplifying the response of CLL cells to other indicators with the microenvironment and rising the activation of anti-apoptotic and proliferation pathways. Duvelisib was the 2nd PI3K inhibitor accepted through the FDA, also according to a section III https://paulp357xce5.blogmazing.com/profile